Arcus Biosciences Inc (RCUS)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Arcus Biosciences Inc chart...

About the Company

arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be

Exchange

NEW YORK STOCK EXCHANGE INC.

Website

arcusbio.com

$457M

Total Revenue

511

Employees

$1B

Market Capitalization

-4.27

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RCUS News

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

25d ago, source: Seeking Alpha

Hello and welcome to the Arcus Biosciences Full Year/Q4 2023 Earnings Call. My name is Elliot, and I’ll be coordinating your call today. [Operator Instructions]. I’d now like to hand over to ...

Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know

25d ago, source: Business Insider

Delving into Arcus Biosciences's Background Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ...

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

26d ago, source: Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

Arcus Biosciences Inc (RCUS)

24d ago, source: Investing

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an ...

Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call Transcript

26d ago, source: Yahoo Finance

Arcus Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to the Arcus Biosciences ...

Arcus Biosciences Inc (RCUS) Reports Fourth-Quarter and Full-Year 2023 Financial Results

27d ago, source: Yahoo Finance

Warning! GuruFocus has detected 4 Warning Signs with RCUS. On February 21, 2024, Arcus Biosciences Inc (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in the development of ...

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

27d ago, source: Stockhouse

cash equivalents and marketable securities and funding into 2027 to support Phase 3 trials for 3 different molecules and launch preparations Conference call today at 2:00 PM PT / 5:00 PM ET Arcus ...

Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Call Transcript

25d ago, source: Insider Monkey

We feel like that’s a great place to go. Insofar as your question about ARC-10 and the strategy there, so clear – let me give a couple of points on that. So clearly, like with many therapies ...

Q4 2023 Arcus Biosciences Inc Earnings Call

26d ago, source: Yahoo Finance

Hello, and welcome to the Arcus Biosciences full year/Q4 2023 earnings call. My name is Elliott, and I'll be coordinating your call today. (Operator Instructions) I'd now like to hand over to Pia ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...